Genmab | GEN - Debt


Genmab reported DKK5.35B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Almirall EUR 342.86M 61.94M Dec/2025
Amarin USD 0 0 Mar/2025
Amgen USD 57.32B 2.72B Mar/2026
argenx SE USD 47.16M 4.01M Dec/2025
AstraZeneca USD 32.24B 1.68B Jun/2026
Bayer EUR 36.45B 2.93B Dec/2025
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Demant DKK 20.99B 4.81B Dec/2025
Exelixis USD 165.93M 3.61M Jun/2026
Fresenius Medical Care EUR 10.96B 66.06M Jun/2026
Genmab DKK 5.35B 5.2B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
GN Store Nord DKK 9.96B 855M Mar/2026
GRIFOLS EUR 8.52B 1.15B Jun/2026
Hikma Pharmaceutical USD 1.6B 46M Dec/2025
Insmed USD 725.8M 1.82M Jun/2026
Lakefront Biotherapeutics EUR 6.44M 480K Mar/2026
Lonza CHF 4.71B 915M Dec/2024
Merck EUR 12.04B 86M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 23.58B 3.56B Jun/2026
UCB EUR 3.03B 12M Dec/2024